Alkermes (ALKS, Financial) experienced a significant stock price surge of 5.02%, reaching $29.09 per share. The trading volume hit 836,742 shares with a turnover rate of 0.52% and a price fluctuation of 5.42%. The recent financial report revealed an operating income of $378 million, a net profit of $92.80 million, earnings per share of $0.57, and a gross profit of $314 million, leading to a price-to-earnings ratio of 14.66.
In terms of analyst ratings, out of 13 institutions, 62% recommended buying, 31% suggested holding, and 7% advised selling the stock. Within the pharmaceutical industry, where Alkermes operates, the overall growth was 0.85%. Among related stocks, Biofrontera Inc., Sunshine Biopharma Inc., and Nature's Sunshine Products showed significant gains. Sunshine Biopharma Inc., Painreform Ltd., and Sonoma Pharmaceuticals, Inc. were notably active, with turnover rates of 1292.97%, 66.67%, and 28.59% respectively. Stocks with significant price fluctuations included Sunshine Biopharma Inc. at 40.52%, Optinose, Inc. at 22.10%, and Scilex Holding Company at 20.38%.
Alkermes is a fully integrated biotechnology company focused on researching, developing, and commercializing pharmaceutical products to address unmet medical needs. The company employs various strategies to develop and commercialize its products, acquiring active pharmaceutical ingredients from third parties or licensees to formulate its products. Alkermes operates primarily in the United States, Ireland, and other global regions, with the U.S. being its largest revenue source.
